Adapt Pharma Limited

After abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to

After abuse-deterrent opioid formulations reached a dead-end, the US FDA is again seeing growth in applications for new products that address the opioid crisis, led by not one but two applications for

Indivior plc is strengthening its market-leading position in addiction treatment by paying $145m to acquire Opiant Pharmaceuticals, Inc. of the US and its promising late-stage nasal spray for opio

An Ohio law allowing pharmacists to provide the opioid overdose reversal drug naloxone without a prescription led to a 2,328% increase in orders dispensed there, according to a study published in the